Simvastatin treatment in the SLO syndrome: A safe approach?

American Journal of Medical Genetics

Volumn 113, Issue 2, 2002, Pages 183-189

  Starck, Lena ^a   Lövgren Sandblom, Anita ^b   Björkhem, Ingemar ^b  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholesterol; Dehydrocholesterols; Dietary choles terol; Simvastatin; Smith Lemli Opitz syndrome; Statin hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; BILE ACID; CHOLESTEROL; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TAUROCHOLIC ACID;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DIET SUPPLEMENTATION; DISEASE EXACERBATION; FEMALE; HUMAN; HYPOCHOLESTEROLEMIA; LIVER TOXICITY; PHOTOSENSITIVITY; POLYNEUROPATHY; PRIORITY JOURNAL; SMITH LEMLI OPITZ SYNDROME;

ADOLESCENT; ALANINE TRANSAMINASE; CHOLESTADIENOLS; DEHYDROCHOLESTEROLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHOTOSENSITIVITY DISORDERS; SIMVASTATIN; SMITH-LEMLI-OPITZ SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037159465     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.10722     Document Type: Article

References (28)

1. Andersson HC, Frentz J, Martinez JE, Tuck-Muller CM, Bellizaire J. 1999. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am J Med Genet 82:382-384.
2. Anstey AV, Ryan A, Rhodes LE, Charman CR, Arlett CF, Tyrrell RM, Taylor CR, Pearse AD. 1999. Characterization of photosensitivity in the Smith-Lemli-Opitz syndrome: A new congenital photosensitivity syndrome. Br J Dermatol 141:406-414.
3. Azurdia RM, Anstey AV, Rhodes LE. 2001. Cholesterol supplementation objectively reduces photosensitivity in the Smith-Lemli-Opitz syndrome. Br J Dermatol 144:143-145.
4. Bottorff M, Hansten P. 2000. Long term safety of hepatic hydroxyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 160:2273-2280.
5. Duplaga BA. 1999. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann Pharmacother 33:1224-1227.
6. Elias ER, Irons M, Hurley AD, Tint GS, Salen G. 1997. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet 68:305-310.
7. Farmer JA, Torre-Aminione G. 2000. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23:197-217.
8. Fitzky BU, Witsch-Baumqartuer M, Erdel M, Lee JN, Paik YK, Glossmen H, et al. 1998. Mutations in the Delta 7-sterol reductase qeue in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci USA 95:8181-8186.
9. Fumagalli R, Smith ME, Urna G, Paoletti R. 1969. The effect of hypocholesteremic agents on myelogenesis. J Neurochem 16:1329-1339.
10. Hartleb M, Rymarczyk G, Januszevsky K. 1999. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 94:1388-1390.
11. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM, Divry P, Hrebieck M, Lehnert W, Sartor K, Trefz FK, Rating D, Bremer HJ, Nyhan WL. 1993. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Paediatrics 91:915-921.
12. Irons MB, Tint GS. 1998. Prenatal diagnosis of Smith-Lemli-Opitz syndrome. Prenat Diagn 18:369-372.
13. Jira PE, Wevers RA, de Jong J, Rubio-Gozalbo E, Smeitink J. 1997. New treatment strategy for Smith-Lemli-Opitz syndrome [letter]. Lancet 349:1222.
14. Jira PE, Wevers RA, de Jong J, Rubio-Gozalbo E, Janssen-Zijlstra FS, van Hejst AF, Sengers RC, Smeitink JA. 2000. Simvastatin: A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res 41:1339-1346.
15. Kelley RI, Hennekam RC. 2000. The Smith-Lemli-Opitz syndrome. J Med Genet 37:321-335.
16. 7-reductase activity in cultured human fibroblasts: A method for the diagnosis of Smith-Lemli-Opitz syndrome. J Inherit Metab Dis 19:59-64.
17. Moebius FF, Fitsky BU, Lee JN, Paik YK, Glossmann H. 1998. Molecular cloning and expression of the human delta7-sterol reductase. Proc Natl Acad Sci USA 95:1899-1902.
18. Natowicz MR, Evans JE. 1994. Abnormal bile acids in the Smith-Lemli-Opitz syndrome. Am J Med Gen 50:364-367.
19. Nowaczyk MJ. 2001. Canadian Paediatric Surveillance Program. Results 2000. Ottawa: Canadian Paediatric Society. p 38-40.
20. Nowaczyk MJ, Nakamura LM, Waye JS. 2001. DHCR7 and Smith-Lemli-Opitz syndrome. Clin Invest Med 24:311-317.
21. Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, Winter RM, Burn J. 1998. Smith-Lemli Opitz syndrome: A variable clinical and biochemical phenotype. J Med Genet 1998 35:558-565.
22. Starck L, Lövgren A. 2000. Diagnosis of Smith-Lemli-Opitz syndrome from stored filter paper specimens. Arch Dis Child 82:490-492.
23. Starck L, Björkhem I, Ritzén EM, Nilsson BY, von Döbeln U. 1999. Beneficial effects of dietary supplementation in a disorder with defective synthesis of cholesterol. A case report of a girl with Smith-Lemli-Opitz syndrome, polyneuropathy and precocious puberty. Acta Paediatr 88:729-733.
24. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, et al. 1994. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 330:107-113.
25. Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, Connor WE, et al. 1998. Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet 63:55-62.
26. Waterham HR, Wanders RJ. 2000. Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim Biophys Acta 1529:340-356.
27. Witsch-Baumgartner M, Fitsky BU, Ogorekova M, Kraft HG, Moebius FF, Glossmann H, Seedorf U, Gillessen-Kaesbach G, Hoffmann GF, ClaytonP, Kelley RI, Utermann HG. 2000. Mutational spectrum in the △7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet 66:402-412.
28. 7-dehydrocholesterol reductase mutations in patients with the Smith-Lemli-Opitz syndrome. Hum Mol Gen 9:1385-1391.